Drug Delivery Strategies for Antivirals against Hepatitis B Virus.
Latavia SinghSunaina IndermunMershen GovenderPradeep KumarLisa C du ToitYahya E ChoonaraViness PillayPublished in: Viruses (2018)
Chronic hepatitis B virus (HBV) infection poses a significant health challenge due to associated morbidity and mortality from cirrhosis and hepatocellular cancer that eventually results in the breakdown of liver functionality. Nanotechnology has the potential to play a pivotal role in reducing viral load levels and drug-resistant HBV through drug targeting, thus reducing the rate of evolution of the disease. Apart from tissue targeting, intracellular delivery of a wide range of drugs is necessary to exert a therapeutic action in the affected organelles. This review encompasses the strategies and techniques that have been utilized to target the HBV-infected nuclei in liver hepatocytes, with a significant look at the new insights and most recent advances in drug carriers and their role in anti-HBV therapy.
Keyphrases
- hepatitis b virus
- drug resistant
- drug delivery
- liver failure
- cancer therapy
- multidrug resistant
- acinetobacter baumannii
- drug induced
- public health
- liver injury
- papillary thyroid
- mental health
- squamous cell carcinoma
- squamous cell
- mesenchymal stem cells
- human health
- climate change
- bone marrow
- risk assessment
- cystic fibrosis
- smoking cessation
- cell therapy